Intravenous Ferric Carboxymaltose Compared with Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania (Ferinject Trial)
Intravenous iron preparations have been shown to be superior to oral iron and have largely replaced the treatment of anemia in Northern countries. However, the socioeconomic and medical conditions in low resource countries greatly differ from those in northern countries. Patients’ different access to medication supply, perception of medication need and compliance as well as the burden of concomitant disease like malaria, soil-transmitted helminths, schistosomiasis, HIV and red blood cells (RBC) genetic disorders may influence effectiveness and safety of iron substitution modality. The aim of the study is to compare iv iron substitution by ferric carboxymaltose (Ferinject®) to per oral iron substitution in a low resource country.
Primary objective: To assess the superiority in terms of effectiveness of intravenous iron substitution with ferric carboxymaltose versus per oral iron substitution for women with iron deficient anemia at delivery in Tanzania.
Secondary objectives: 1) To evaluate safety and feasibility of intravenous ferric carboxymaltose substitution compared to per oral iron substitution in a resource limited country. 2) To evaluate acceptance of intravenous ferric carboxymaltose substitution compared to per oral iron substitution in a resource limited country, 3) To evaluate health and wellbeing of women receiving intravenous ferric carboxymaltose compared to women receiving per oral iron substitution, 4) To evaluate the sensitivity of diagnosis of iron deficiency by measuring hemoglobin, mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) only, compared to the diagnosis by measuring iron metabolism parameters in a resource limited country.